Meeting
2013 ASCO Annual Meeting
Antitumor activity of concurrent blockade of immune checkpoint molecules CTLA-4 and PD-1 in preclinical models.
Authors
Mark Selby
Bristol-Myers Squibb, Redwood City, CA
Mark Selby , John Engelhardt , Li-Sheng Lu , Michael Quigley , Changyu Wang , Bingliang Chen , Alan J. Korman
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics - Immunotherapy
Track
Developmental Therapeutics
Sub Track
Immunotherapy and Biologic Therapy
Citation
J Clin Oncol 31, 2013 (suppl; abstr 3061)
DOI
10.1200/jco.2013.31.15_suppl.3061
Abstract #
3061
Poster Bd #
16D
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Combining ipilimumab (ipi) and nivolumab (nivo) in advanced melanoma following progression on a PD-1 inhibitor (SWOG S1616).
First Author: Ari M. Vanderwalde
Poster
2013 ASCO Annual Meeting
Nonclinical evaluation of the combination of mouse IL-21 and anti- mouse CTLA-4 or PD-1 blocking antibodies in mouse tumor models.
First Author: Maria Jure-Kunkel
Poster
2019 ASCO Annual Meeting
A phase I, first-in-human, open label, dose-escalation and cohort expansion study of MGD019, a bispecific DART protein binding PD-1 and CTLA-4 in patients with unresectable or metastatic neoplasms.
First Author: Jason J. Luke
Poster
2017 ASCO Annual Meeting
Checkmate 743: A phase 3, randomized, open-label trial of nivolumab (nivo) plus ipilimumab (ipi) vs pemetrexed plus cisplatin or carboplatin as first-line therapy in unresectable pleural mesothelioma.
First Author: Gerard Zalcman